# Safety and Efficacy Study of Sublingual Immunotherapy (SLIT) to Treat House Dust Mite Allergic Rhinitis

> **NCT00674700** · PHASE2,PHASE3 · COMPLETED · sponsor: **Stallergenes Greer** · enrollment: 509 (actual)

## Conditions studied

- Allergic Rhinitis

## Interventions

- **DRUG:** 300 IR house dust mites allergen extract tablet
- **DRUG:** 500 IR house dust mites allergen extract tablet
- **DRUG:** Placebo tablet

## Key facts

- **NCT ID:** NCT00674700
- **Lead sponsor:** Stallergenes Greer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** 2009-02
- **Final completion:** 2010-02
- **Target enrollment:** 509 (ACTUAL)
- **Last updated:** 2016-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00674700

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00674700, "Safety and Efficacy Study of Sublingual Immunotherapy (SLIT) to Treat House Dust Mite Allergic Rhinitis". Retrieved via AI Analytics 2026-09-26 from https://api.ai-analytics.org/clinical/NCT00674700. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*